All In Biotech

Drug Trial Radar · NCT07349537

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

574

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Apr 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • PDAC
  • CRC
  • NSCLC
  • Pancreatic Cancer
  • Lung Cancer (NSCLC)
  • Advanced Solid Tumors

Interventions

  • RMC-5127Drug

    oral tablets

  • daraxonrasibDrug

    oral tablets

  • cetuximabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events (AEs)Time frame: Up to approximately 3 years
  2. Changes in vital signsTime frame: Up to approximately 3 years
  3. Changes in electrocardiogram (ECG) test valuesTime frame: Up to approximately 3 years
  4. Changes in clinical laboratory test valuesTime frame: Up to approximately 3 years
  5. Dose Limiting ToxicitiesTime frame: Up to 28 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • NEXT - Dallas

    Dallas, Texas · Recruiting

  • NEXT

    San Antonio, Texas · Recruiting

  • START - San Antonio

    San Antonio, Texas · Recruiting

  • NEXT - Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.